Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this article the long term results have improved decade after decade. Still there is space for improvements. Even if it is a small part of the whole ALL treatment protocol, it is worth having the lumbar punctures right the first time.

“Among ALL survivors, it was found that late mortality continued to decrease over treatment decades. This was highly attributable to a decrease in mortality from relapse.”

Read the publication from here: Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study Pediatr Blood Cancer. 2022;

Gitte V. Sørensen1,2 Federica Belmonte3 Friederike Erdmann4,5 Hanna Mogensen6 Vanna Albieri3 Anna S. Holmqvist7 Laura Madanat-Harjuoja8 Mats Talbäck6 Mats M. Heyman9 Nea Malila8 Maria Feychting6
Kjeld Schmiegelow10 Jeanette F. Winther2,4 Henrik Hasle1

1 Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
2 Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, Aarhus, Denmark
3 Unit of Statistics and Data Analysis, Danish Cancer Society Research Center, Copenhagen, Denmark
4 Childhood Cancer Research Group, Danish Cancer Society Research Center, Copenhagen, Denmark
5 Division of Childhood Cancer Epidemiology, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg
University Mainz, Mainz, Germany
6 Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
7 Department of Clinical Sciences, Lund University, Pediatric Oncology and Hematology, Skåne University Hospital, Lund, Sweden
8 Finnish Cancer Registry, Helsinki, Finland
9 Childhood Cancer Research Unit, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
10 Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark

 

Injeq participating SIOP 2022 in Barcelona 28th September -1st October

Injeq is very excited to attend the SIOP Congress to present our amazing IQ-Tip system to doctors, patients and their […]
Read more »

Late mortality among survivors of childhood acute lymphoblastic leukemia diagnosed during 1971–2008 in Denmark, Finland, and Sweden: A population-based cohort study

An interesting article from Sørensen et al. about long term survival from childhood ALL (acute lymphoblastic leukemia). According to this […]
Read more »

German reseller Florian Holderer was dazzled by the smart needle

Ecumed’s CEO Florian Holderer emphasizes the importance of user experience and trust in the marketing of the IQ-Tip®​ smart needle. Florian Holderer […]
Read more »

Changes to the Injeq Plc. Board

The Annual General Meeting held on May 31 2022 made the regular decisions as defined in the by-laws. The new […]
Read more »

Incidence of traumatic lumbar punctures in neonates and infants

The part two of the trilogy has now been published. This article of the three part series examines the incidence […]
Read more »

Injeq whitepaper on lumbar puncture

Our whitepaper takes a closer look at the lumbar puncture, the IQ-Tip® system’s first indication, and presents the results that […]
Read more »